Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxazepam
Drug ID BADD_D01636
Description Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.[L13895]
Indications and Usage For the treatment of anxiety disorders and alcohol withdrawal.
Marketing Status Prescription; Discontinued
ATC Code N05BA04
DrugBank ID DB00842
KEGG ID D00464
MeSH ID D010076
PubChem ID 4616
TTD Drug ID D09LDR
NDC Product Code 62584-812; 43353-965; 62584-813; 0228-2067; 72166-009; 64330-015; 0228-2069; 67544-117; 71610-639; 0228-2073; 43353-980; 48087-0087; 62584-814; 12828-0024; 52817-292; 52817-290; 52817-291; 67544-268
Synonyms Oxazepam | Serax | Tazepam | Adumbran
Chemical Information
Molecular Formula C15H11ClN2O2
CAS Registry Number 604-75-1
SMILES C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Intentional self-injury12.01.08.036; 19.12.01.0020.013932%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lactic acidosis14.01.01.0020.006966%Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.0040.006966%Not Available
Malaise08.01.01.0030.017415%
Memory impairment19.20.01.003; 17.03.02.003--
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscle spasms15.05.03.0040.006966%
Mydriasis17.02.11.003; 06.05.03.0040.017415%Not Available
Myocardial infarction24.04.04.009; 02.02.02.0070.001817%
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.0050.001817%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.0040.010449%
Palpitations02.01.02.0030.006966%
Pancreatitis07.18.01.0010.001817%
Paraesthesia17.02.06.005--
Pneumonia aspiration22.01.01.0050.001817%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.0030.001817%
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005--Not Available
Renal failure20.01.03.0050.006966%Not Available
Respiratory acidosis22.02.02.004; 14.01.04.0020.006966%Not Available
Respiratory arrest22.02.01.0090.001817%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001817%
Restlessness19.11.02.002; 17.02.05.0210.010449%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages